Monday, August 31, 2026

Tilray Shares Plunge Over 25% In Recent 10 Sessions

ViaNews Editorial Team

September 25, 2023

Tilray Shares Plunge Over 25% In Recent 10 Sessions

(VIANEWS) - Tilray (NASDAQ:TLRY) stock has seen its share price decline 25.38% in 10 sessions from EUR3.31 at 2023-09-11 to EUR2.47 as of 11:39 EST Monday after an upward trend. Meanwhile, the NASDAQ index fell 0.09% to EUR13,199.38 following four straight sessions of losses; Tilray's last closing price was EUR2.40 representing 53.13% decline since reaching its 52-week high of EUR5.12.

About Tilray

Tilray Brands is an international company engaged in research, cultivation, processing and distribution of medical cannabis products across various countries. Under four segments - Cannabis, Distribution, Beverage Alcohol and Wellness - this company offers an expansive selection of products such as medical and adult-use cannabis; pharmaceutical and wellness products; hemp-based food and beverage alcohol products and more. Tilray Brands sells its products under various brand names to a broad spectrum of customers, such as retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers and governments - both directly and through distributors. Formerly known as Tilray Inc. in Canada.

Yearly Analysis

Investment Prospect: Tilray Inc. (NASDAQ:TLRY), a Canadian cannabis company that cultivates, processes and distributes cannabis and hemp products is currently trading at EUR2.47, below its 52-week high of EUR5.12 but above its low point of EUR1.50. Tilray anticipates sales growth of 16.2% for 2023 and 9.8% for 2024 - providing evidence of its tremendous expansion potential. Tilray currently stands with an EBITDA figure of 2.85, representing its operating profits. While this number doesn't offer specific context around industry benchmarks or historical performance comparisons, an increasing EBITDA over time generally speaks well of a company. According to the provided data, Tilray appears undervalued relative to its 52-week high and expected sales growth is projected. Unfortunately, without additional information regarding financial performance benchmarks or key factors it is difficult to provide an accurate investment outlook; before making any definitive investment decisions further research and analysis must be performed.

Technical Analysis

Tilray Inc. (TLRY) stock prices have experienced a rollercoaster ride recently, as their current value stands significantly above both its 50-day moving average of EUR2.02 and 200-day moving average of EUR2.63. This indicates that Tilray's shares have been volatile. Furthermore, their last reported volume of 7,360,020 falls 77.69% short of their average volume of 31,437,500; suggesting traders may be taking a wait-and-see approach when making decisions about this stock. Tilray stock's volatility was evident over the last week, month and quarter with average intraday variation averages of negative 1.65%, positive 0.11% and positive 5.21% for each, with its highest amplitude being 2.28% in each instance - raising concerns of investors as it indicates price changes could happen quickly and dramatically. Overall, Tilray's stock price has seen many fluctuations, prompting investors to be wary when investing in its shares. Investors should monitor Tilray's performance, moving averages and volatility closely so as to make informed investment decisions.

Quarter Analysis

Tilray's current quarter sales growth is 13.6%, showing that its revenues continue to expand at an impressive pace. Growth estimates for both this and next quarters stand at 61.54% and 54.45%, suggesting Tilray may continue its revenue expansion at an equally impressive pace in coming quarters. Tilray has achieved year-on-year quarterly revenue growth of 20.1% with twelve-month trailing revenues totalling 627.12M; this indicates expansion and market expansion for Tilray. Overall, Tilray appears to be an attractive investment option with projected strong sales and revenue growth over the short and medium terms. Investors should conduct additional research in order to fully comprehend its financial condition and any associated risks before making investment decisions.

Equity Analysis

Tilray currently generates negative EPS over its past twelve month period, suggesting it does not produce profits for shareholders. Return on Equity (ROE) for the twelve trailing months stands at negative -37.14%, suggesting that profits are being generated inefficiently relative to shareholder's equity. This should cause serious concern among potential investors as a negative ROE indicates that assets may not be properly leveraged to generate profits and return. Overall, Tilray may not represent an attractive investment opportunity at present given that its current profitability and asset utilization levels do not generate profits for investors. Before making their final investment decision, investors may wish to carefully consider these financial metrics along with any qualitative information and qualitative insight available before making their final choice.

More news about Tilray (TLRY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com